DexCom (DXCM) Stock Forecast & Price Prediction

Estimation of the future price movement of DexCom stock, based on various factors such as historical price trends, market trends, company performance, and economic conditions.

Price target


Current $116.65

Concensus $75.37


Low $28.13

Median $41.25

High $146.00

Based on analysts projections #DXCM is expected to experience a price decline over the next year.

The current average DXCM price target, as estimated by these analysts, is $75.37.

The predictions for the future DXCM stock price range from a low of $28.13 to a high of $146.00, highlighting the variability of market expectations for DXCM.

It is important to note that market fluctuations and unforeseen events can have an impact on these projections, so investors should always exercise caution and conduct thorough research before making any investment decisions.

DXCM stock forecasts by analyst

Analyst / firm Date Rating Price target Price when posted
Steven Lichtman
Oppenheimer
October 27, 2023 Buy 122.00 88.91
Morgan Stanley January 6, 2023 Buy 131.00 114.45
Stifel Stifel
Stifel Nicolaus
December 26, 2022 Buy 130.00 111.44
Citigroup December 12, 2022 Buy 146.00 116.64
Matt O'Brien
Piper Sandler
October 7, 2022 Buy 120.00 95.21
Raymond James August 1, 2022 Sell 101.00 82.08
Morgan Stanley July 29, 2022 Sell 83.00 86.99
Matt O'Brien
Piper Sandler
July 28, 2022 Sell 110.00 86.99
Lee Hambright
Bernstein
July 15, 2022 Sell 105.00 76.50
Marie Thibault
BTIG
June 28, 2022 Sell 105.00 76.60
Morgan Stanley June 15, 2022 Sell 91.00 69.31
Morgan Stanley June 13, 2022 Sell 90.75 70.74
Morgan Stanley June 7, 2022 Buy 363.00 19.28
Danielle Antalffy
Leerink Partners
May 3, 2022 Buy 500.00 24.79
Mathew Blackman
Stifel Nicolaus
May 3, 2022 Buy 520.00 24.79
Raymond James April 29, 2022 Buy 486.00 26.05
Piper Sandler April 29, 2022 Buy 480.00 25.83
Marie Thibault
BTIG
April 21, 2022 Buy 560.00 31.02
Travis Steed
Bank of America Securities
March 3, 2022 Buy 500.00 26.50
Joanna Wuensch
Citigroup
February 11, 2022 Buy 630.00 26.29
Steven Lichtman
Oppenheimer
January 31, 2022 Buy 580.00 26.91
Jayson Bedford
Raymond James
January 19, 2022 Buy 538.00 27.20
Larry Biegelsen
Wells Fargo
January 19, 2022 Buy 575.00 27.20
Ravi Misra
Berenberg Bank
October 29, 2021 Buy 630.00 38.95
Kyle Rose
Canaccord Genuity
October 29, 2021 Buy 625.00 38.95
Matthew Taylor
UBS
October 29, 2021 Buy 660.00 38.95
Anthony Petrone
Jefferies
October 29, 2021 Buy 655.00 38.95
Chris Cooley
Stephens
July 30, 2021 Buy 546.00 32.22
Robbie Marcus
J.P. Morgan
June 9, 2021 Buy 450.00 24.38

DexCom (DXCM) Fundamentals Checker

Financial metrics are used to evaluate financial stability which helps analysts determine if DexCom is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.

Strong Buy

Financial Scores

Updated on: 29/11/2023

Altman Z-Score: 7.5

Piotroski Score: 6.0

ESG Score

Updated on: 29/11/2023

Environmental: 51.5

Social: 47.7

Governance: 58.9

Financial Health

Updated on: 29/11/2023

DCF: Strong Buy

ROE: Neutral

ROA: Neutral

Debt to equity ratio: Buy

Price to earnings ratio: Strong Buy

Price to book ratio: Strong Buy

DXCM Discounted Cash Flow

Updated on: 29/11/2023

$126.993
Discounted Cash Flow Value


$116.525
Current Price

DXCM Revenues by Segment

Updated on: 29/11/2023

No available data

Revenue from Contract with Customer, Excluding Assessed Tax

DXCM Revenues by Region

Updated on: 29/11/2023

Non-US
$7,678,000.00
UNITED STATES
$21,420,000.00

DXCM Notes Due

Updated on: 29/11/2023

CIKExchangeTitle
0001093557 NASDAQ Preferred Stock Purchase Rights, $0.001 Par Value Per Share

DexCom (DXCM) Social Sentiments

Monitoring bullish and bearish sentiments towards DexCom on Twitter and Stocktwits could help to forecast an upward or downward trend in DexCom stock price.

No social results for DXCM

Outperforming the Competition: A Promising Stock Forecast for DexCom (DXCM)

DexCom (DXCM) is a leading medical devices company that specializes in glucose monitoring systems used by people with diabetes. The company's innovative technology empowers patients to control their diabetes effectively and improve their quality of life. Since its inception, DexCom has been committed to providing reliable, accurate, and affordable continuous glucose monitoring solutions. The company's products include the Dexcom G6...
Furthermore, according to Yahoo Finance analysis powered by Benzinga Pro on June 24th stated DXCM has Outperform rating across eleven different types of analyst sources including Hedge Funds , Bloggers , Individual Traders etc.

DexCom's shares have outperformed both the S&P 500 index and industry peers in recent years. In 2023 alone, DXCM's share price grew by more than 65%, significantly outperforming the S&P 500 which increased by only around $16%.

In summary, DexCom is one of the leading players in the medical devices sector committed to improving patients' quality lives suffering from diabetes through innovative technology solutions providing continuous glucose monitoring systems safe-for-use without specified times interval with automatic stop-in-sensor function outside recommended ranges.

Looking at relevant data from trusted sources, analysts are confident that DXCM's share price will continue to rise in the coming years. If you are a savvy investor seeking promising stock forecast with a strong track record of growth and innovation, DexCom (DXCM) is definitely one company you should keep your eyes on.">Read more

Revolutionizing Healthcare: DexCom's Strong Stock Prediction in the Medical Devices Sector

Medical devices have revolutionized the way healthcare is provided to patients. The medical devices sector has experienced tremendous growth in recent years, thanks to advancements in technology and an aging population. Investors can benefit from this growth by investing in the stock market sector of medical devices. One company that has gained significant attention in this sector is DexCom (DXCM),... Read more